Converging lines of evidence suggest that men generally smoke for nicotine-related reinforcement, whereas women smoke for non-nicotine factors. Women have more difficulty quitting smoking and are less responsive to nicotine replacement therapies than men, underscoring the importance of examining sex differences in the neurochemical mechanisms underlying nicotine-motivated behavior. We review the recent imaging literature on sex differences in the nicotinic acetylcholine receptor system and in the dopaminergic system in response to nicotine administration and tobacco smoking. We offer an explanation to unify imaging findings related to the dopamine system. We then propose a course of action for future medication development for tobacco smoking addiction.
Introduction
Tobacco smoking is the leading cause of morbidity and mortality in the United States [1] , with nearly 556 000 deaths attributable to smoking-related causes each year [2] . The prevalence of smoking continues to be greater in men (20.5%) than women (15.3%) [3] ; however, women have worse treatment outcomes. Specifically, women have a more difficult time quitting smoking than men [4] and currently-approved treatments for smoking, including nicotine replacement therapies (NRT) and bupropion, are not as effective in women as in men [5 ] .
This underscores the importance of examining sex differences in the neurobiological mechanisms underlying tobacco smoking-related behaviors to optimize sex-[ 9 _ T D $ D I F F ] appropriate treatment strategies for nicotine dependence.
In the following sections, we will review the recent receptor imaging literature on sex differences in the tobacco smoking field in first, nicotinic acetylcholine receptor (nAChR) availability, and second, dopamine (DA) receptor availability and neurotransmission. We conclude with a figure integrating findings of sex differences within the mesolimbic and mesocortical dopaminergic (DA-ergic) neural systems. We outline how these findings can inform 
The nAChR system
Background Nicotine is the primary addictive chemical in cigarettes.
In the brain, nicotine binds to and activates nAChRs. Some of the most abundant nAChRs in the brain are those containing the a4 and b2 subunits, and the reinforcing effects of nicotine are mediated by nAChRs, specifically containing the b2 subunit [6, 7] . The b2 subunit is critical for nicotine-induced DA release, behavioral responses to nicotine such as nicotine self-administration, conditioned reinforcement, conditioned place preference (CPP), and locomotor activation [7] . Seminal preclinical and postmortem human studies consistently demonstrate that nicotine robustly increases or 'upregulates' the b2-subunit containing nAChRs (b2-nAChRs) throughout the brain (for review see Cosgrove et al. [8] ). Imaging studies have translated these findings to humans, in vivo.
Imaging the upregulation of b2-nAChRs in smokers
Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are important imaging techniques used to measure chemicals in the living brain, such as receptors[ 1 _ T D $ D I F F ] and fluctuations in neurotransmitter levels. Radiotracers, when injected into a living subject, allow us to measure these brain chemicals with a PET or SPECT camera. Several radiotracers have been designed to bind to b2-nAChRs and are used to measure b2-nAChR availability. This is particularly useful for identifying neurochemical mechanisms underlying
